We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
We are a team of access specialists with decades of experience working in the pharmaceutical, biotech and medical technology sectors, within industry, in consulting and in the policy arena.
Our aim is to provide you with the knowledge and understanding to help you address your access challenges, and to continue to keep up to date in this rapidly changing field.
Regular news articles and monthly newsletters keep you informed about important developments in access policy and practice worldwide.
We help access professionals understand the complex processes and policies they need to follow, ensuring that innovative treatments reach patients with minimal delay.
Our international calendar of events connects you directly to the latest thinking and developments in access and helps you to grow your professional network.
The UK will zero-rate qualifying free medicine supplies for NHS treatment, clinical trials and post-trial care, with interim tax relief applying from June 2026.
AIFA has finalised company-level liabilities for the 2025 direct-purchase medicines overspend, leaving the previously announced €2.385 billion total unchanged and triggering payment obligations.
Poland’s Government has approved a broad reimbursement bill combining simpler procedures, new orphan-medicine assessment provisions and incentives for domestic pharmaceutical production.
An interactive training course on negotiating with healthcare payers. Participants examine negotiation objectives, tactics, stakeholder perspectives and case-based approaches to pharmaceutical pricing and reimbursement discussions.
This German-language seminar examines scientific advice from regulatory and HTA authorities and how national and European consultation processes can inform pharmaceutical market access strategy.
Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.
How healthcare is financed, commissioned and delivered in England, Scotland, Wales and Northern Ireland, including provider organisation and patient charges.
How clinical and economic assessment shapes NHS medicines funding, including NICE appraisal, Scottish assessment and the arrangements in Wales and Northern Ireland.
The MHRA's procedures for authorising medicines in the UK, including national assessment, international recognition, conditional approval and coordination with NICE.